zevra_inline_fullcolor_rgb_12in@300ppi (1).png
Zevra Therapeutics to Participate at Upcoming Investor Conferences
August 29, 2024 07:30 ET | Zevra Therapeutics
CELEBRATION, Fla., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane,...
zevra_inline_fullcolor_rgb_12in@300ppi (1).png
Zevra Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights
August 13, 2024 16:05 ET | Zevra Therapeutics
FDA advisory committee voted favorably that the data support arimoclomol as effective treatment for patients with NPC; PDUFA date of September 21, 2024 Pro forma June 30, 2024, cash, cash...
zevra_inline_fullcolor_rgb_12in@300ppi (1).png
Zevra Therapeutics Announces Pricing of Underwritten Offering of Common Stock
August 09, 2024 00:00 ET | Zevra Therapeutics
CELEBRATION, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a rare disease therapeutics company (“Zevra”), today announced the pricing of an underwritten public...
zevra_inline_fullcolor_rgb_12in@300ppi (1).png
Zevra Therapeutics Announces Proposed Public Offering of Common Stock
August 08, 2024 16:01 ET | Zevra Therapeutics
CELEBRATION, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a rare disease therapeutics company (“Zevra”), today announced the commencement of a proposed...
zevra_inline_fullcolor_rgb_12in@300ppi (1).png
Zevra Therapeutics to Present at Canaccord Genuity’s 44th Annual Growth Conference
August 07, 2024 09:34 ET | Zevra Therapeutics
CELEBRATION, Fla., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane,...
zevra_inline_fullcolor_rgb_12in@300ppi (1).png
FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C
August 02, 2024 17:50 ET | Zevra Therapeutics
CELEBRATION, Fla., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that the U.S. Food and...
zevra_inline_fullcolor_rgb_12in@300ppi (1).png
Zevra Therapeutics to Report Second Quarter 2024 Financial Results
July 30, 2024 08:38 ET | Zevra Therapeutics
CELEBRATION, Fla., July 30, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a rare disease therapeutics company, today announced that it will host a...
zevra_inline_fullcolor_rgb_12in@300ppi (1).png
Zevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C
July 09, 2024 09:00 ET | Zevra Therapeutics
CELEBRATION, Fla., July 09, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that the U.S. Food and...
zevra_inline_fullcolor_rgb_12in@300ppi (1).png
Zevra Therapeutics Expands Executive Leadership Team
June 25, 2024 07:30 ET | Zevra Therapeutics
Rahsaan W. Thompson appointed as Chief Legal Officer, Secretary and Compliance Officer Alison Peters appointed as Chief People Officer CELEBRATION, Fla., June 25, 2024 (GLOBE NEWSWIRE) -- Zevra...
zevra_inline_fullcolor_rgb_12in@300ppi (1).png
Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders
June 18, 2024 07:30 ET | Zevra Therapeutics
CELEBRATION, Fla. and ELK GROVE VILLAGE, Ill., June 18, 2024 (GLOBE NEWSWIRE) -- Orsini Specialty Pharmacy (Orsini), and Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra) today announced that Orsini...